Effects of interleukin-2 immunotherapy on soluble lymphocyte markers in cancer patients.
Lissoni
P
P
Rovelli
F
F
Tisi
E
E
Ballabio
D
D
Benenti
C
C
Ardizzoia
A
A
Barni
S
S
Tancini
B
B
D000328:Adult; D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D012995:Solubility
D000945:Antigens, Differentiation, T-Lymphocyte; D015415:Biomarkers; D015704:CD4 Antigens; D016827:CD8 Antigens; D007376:Interleukin-2; D015375:Receptors, Interleukin-2